A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Pfizer
Pfizer
City of Hope Medical Center
Novartis
University of Pittsburgh
Compugen Ltd
Intensity Therapeutics, Inc.
NextCure, Inc.
ADC Therapeutics S.A.
Kineta Inc.